1. Home
  2. IMOS vs SVRA Comparison

IMOS vs SVRA Comparison

Compare IMOS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMOS

ChipMOS TECHNOLOGIES INC.

HOLD

Current Price

$34.47

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

SVRA

Savara Inc.

HOLD

Current Price

$5.69

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMOS
SVRA
Founded
1997
2007
Country
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IMOS
SVRA
Price
$34.47
$5.69
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$7.33
AVG Volume (30 Days)
38.8K
1.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.37
N/A
Revenue Next Year
$11.46
N/A
P/E Ratio
$158.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.78
$1.89
52 Week High
$45.43
$7.01

Technical Indicators

Market Signals
Indicator
IMOS
SVRA
Relative Strength Index (RSI) 45.91 50.93
Support Level $33.88 $5.44
Resistance Level $35.91 $6.06
Average True Range (ATR) 1.35 0.35
MACD -0.53 0.04
Stochastic Oscillator 22.45 61.14

Price Performance

Historical Comparison
IMOS
SVRA

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Share on Social Networks: